A fusion protein containing the full length SARS-CoV-2 spike protein, or the S1 domain or the S2 domain of the SARS-CoV-2 spike protein or a fragment, or the human Angiotensin Converting Enzyme 2 (ACE2) receptor of the SARS-CoV-2 spike protein or a fragment, and a N-terminal signal peptide, and at least one of the following: a polyhistidine tag, a streptavidin binding domain, a linker, or an oligomerization tag.
The present invention relates to a method for detecting at least one target nucleic acid sequence from a nucleic acid mixture by a double quenched assay. The double quenched assay of the method exploits a novel approach for melting temperature mediated identification of multiple target nucleic acid sequences. The invention further relates to a kit of parts.
C12Q 1/6818 - Tests d’hybridation caractérisés par les moyens de détection impliquant l’interaction de plusieurs marqueurs, p. ex. transfert d’énergie de résonance
3.
DUAL QUENCHING ASSAY FOR MULTIPLEX DETECTION OF TARGET NUCLEIC ACIDS
The present invention relates to a method for detecting at least one target nucleic acid sequence from a nucleic acid mixture by a double quenched assay. The double quenched assay of the method exploits a novel approach for melting temperature mediated identification of multiple target nucleic acid sequences. The invention further relates to a kit of parts.
C12Q 1/6818 - Tests d’hybridation caractérisés par les moyens de détection impliquant l’interaction de plusieurs marqueurs, p. ex. transfert d’énergie de résonance
A fusion protein includes the SARS-COV-2 receptor binding domain (RBD) of the SARS-COV-2 spike protein or a fragment, and a N-terminal signal peptide, and at least one of the following: a polyhistidine tag, linker, an oligomerization tag, a region in spike protein outside RBD, a horseradish peroxidase binding domain or a protease cleavage site.
An anti-HIV-1 antibody comprising L-CDR1, L-CDR2 and L-CDR3, wherein L-CDR1 is selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21, and a sequence that differs from anyone of SEQ ID NOs: 15, 18, or 21 by one or two substitutions, deletions, or additions, the amino acid sequence of L-CDR2 is selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 22, and a sequence that differs from anyone of SEQ ID NOs: 16, 19, or 22 by one or two substitutions, deletions, or additions, and the amino acid sequence of L-CDR3 is selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, and a sequence that differs from anyone of SEQ ID NOs: 17, 20, or 23 by one or two substitutions, deletions, or additions.
C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
6.
COMPOSITIONS, METHODS AND/OR KITS COMPRISING A RECOMBINANT HUMAN CD38-EXTRACELLULAR DOMAIN
A composition that binds to an anti-CD38 antibody includes a specific sequence of a recombinant soluble form of an extracellular domain of CD38 and/or a fragment thereof that interferes with binding activity of the anti-CD38 antibody. The composition can be included in a kit for bio-monitoring research and diagnostic assays. The composition can be used to neutralize an anti-CD38 antibody in a sample and/or to select a suitable red blood cell unit for a patient treated with anti-CD38 antibodies.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/80 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir les groupes ou les types sanguins
7.
COMPOSITIONS AND METHODS FOR STORING A BIOLOGICAL SAMPLE
Aqueous compositions are for storing a biological sample for subsequent nucleic acid testing. The compositions include a first component, which includes an anionic detergent in an amount from about 1% to 20% (w/v), a Group I metal hydroxide in an amount from about 1% to 5% (w/v), a chelating agent in an amount from about 0.5% to 5% (w/v), and a first buffer. The composition further includes a diluting component selected from water, a second buffer, a Transport Medium, Sodium Chloride (aq), and combinations. The first component can be diluted up to a maximum of about 50% (v/v) with the diluting component.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p. ex. pour test de réaction en chaîne par polymérase [PCR]
G01N 1/10 - Dispositifs pour prélever des échantillons à l'état liquide ou fluide
8.
IMMUNOASSAYS AND ENGINEERED PROTEINS FOR MONITORING ANTIBODY TREATMENTS TO THE IMMUNE CHECKPOINT INHIBITORS PD1 AND PD-L1
Fusion proteins include an extracellular domain of PD1 protein (programmed cell death protein-1) and/or an extracellular domain of PD-L1 protein (programmed cell death-ligand 1 protein (CD274 or B7-H1)). Portions of the extracellular domains are expressed in specific configurations and purified as protein, which are used in immunoassays to monitor the circulating levels of biotherapeutic antibodies to these proteins. A method is for determining the amount of circulating levels of a biotherapeutic antibody in a biological sample obtained from a patient when the patient has undergone at least one dose of immunotherapy.
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
9.
COMPOSITIONS, METHODS AND/OR KITS COMPRISING A RECOMBINANT HUMAN CD38-EXTRACELLULAR DOMAIN
A composition that binds to an anti-CD47 antibody includes a specific sequence of a recombinant soluble form of an extracellular domain of CD47 and/or a fragment thereof that interferes with binding activity of the anti-CD47 antibody. The composition can be included in a kit for bio-monitoring research and diagnostic assays. The composition can be used to neutralize an anti-CD47 antibody in a sample and/or to select a suitable red blood cell unit for a patient treated with anti-CD47 antibodies.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/80 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir les groupes ou les types sanguins
10.
Methods and Compositions for Treating Aging-Associated Impairments with TIMP-2 Recombinant Proteins
Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include recombinant protein constructs employing human TIMP-2 protein for use in treating indications related to aging-related cognitive impairment.
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
11.
METHODS AND COMPOSITIONS FOR TREATING AGING-ASSOCIATED IMPAIRMENTS WITH TIMP-2 RECOMBINANT PROTEINS
Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include recombinant protein constructs employing human TIMP-2 protein for use in treating indications related to aging-related cognitive impairment.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 38/00 - Préparations médicinales contenant des peptides
A fusion protein includes a SARS-CoV-2 nucleocapsid N-terminal domain and/or a SARS-CoV-2 nucleocapsid C-terminal domain, wherein the fusion protein lacks the SARS-CoV-2 nucleocapsid aggregation domain.
The medical field of COVID-19 diagnosis relates to methods for detecting SARS-CoV-2 nucleic acids in a sample as well as combinations of oligomers for determining the presence or absence of SARS-CoV-2 in a Sample.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
14.
COMPOSITIONS AND METHODS FOR STORING A BIOLOGICAL SAMPLE
The present invention refers to aqueous compositions for storing a biological sample for subsequent nucleic acid testing, the compositions comprising a first component comprising: i) an anionic detergent in an amount from about 1 % to 20 % (w/v), ii) a Group I metal hydroxide in an amount from about 1 % to 5% (w/v), iii) a chelating agent in an amount from about 0.5 % to 5 % (w/v), and iv) a first buffer, wherein the composition further comprises a diluting component selected from the group consisting of water, a second buffer, a Transport Medium, Sodium Chloride (aq), and combinations thereof, wherein the first component is diluted up to a maximum of about 50 % (v/v) with the diluting component.
Disclosed are nucleic acid oligomers, including amplification oligomers, detection probes, and capture probes, for detection of Plasmodium species nucleic acid in a sample. Also disclosed are methods of specific nucleic acid amplification and detection, including amplification and detection of target nucleic acid in real time, using the disclosed oligomers, as well as corresponding reaction
C12Q 1/6893 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les protozoaires
A device for breaking cells that has a reactor with a reaction chamber, an agitator, a cooling jacket, a cooling jacket inlet, a cooling jacket outlet, a sampling port, and a temperature probe insertion fitting, and a motor suitable for mounting the reactor on its top and which is operably connected with the agitator. A system for breaking cells comprising at least one device, at least one temperature probe inserted in the temperature probe insertion fitting of the device, a cooling system operably connected to the temperature probe, and an electronic control panel. The cooling system has at least one solenoid valve, each device of the system having one corresponding solenoid valve.
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 1/02 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens d'agitationAppareillage pour l'enzymologie ou la microbiologie avec des moyens d'échange de chaleur
The present invention refers to fusion proteins comprising a SARS-CoV-2 nucleocapsid N-terminal domain and/or a SARS-CoV-2 nucleocapsid C-terminal domain, wherein said fusion protein lacks the SARS-CoV-2 nucleocapsid aggregation domain.
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
A fusion protein comprising the SARS-CoV-2 receptor binding domain (RBD) of the SARS-CoV-2 spike protein or a fragment thereof, and a N-terminal signal peptide, and at least one of a polyhistidine tag, linker, an oligomerization tag, a region in spike protein outside RBD, a horseradish peroxidase binding domain or a protease cleavage site.
A fusion protein comprising the full length SARS-CoV-2 spike protein, or the S1 domain or the S2 domain of the SARS-CoV-2 spike protein or a fragment thereof, or the human Angiotensin Converting Enzyme 2 (ACE2) receptor of the SARS-CoV-2 spike protein or a fragment thereof, and a N-terminal signal peptide, and at least one of a polyhistidine tag, a streptavidin binding domain, a linker, or an oligomerization tag.
An anti-HIV-1 antibody comprising L-CDR1, L-CDR2 and L-CDR3, wherein L-CDR1 is selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21, and a sequence that differs from anyone of SEQ ID NOs: 15, 18, or 21 by one or two substitutions, deletions, or additions, the amino acid sequence of L-CDR2 is selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 22, and a sequence that differs from anyone of SEQ ID NOs: 16, 19, or 22 by one or two substitutions, deletions, or additions, and the amino acid sequence of L-CDR3 is selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, and a sequence that differs from anyone of SEQ ID NOs: 17, 20, or 23 by one or two substitutions, deletions, or additions.
An anti-HIV-1 antibody comprising L-CDR1, L-CDR2 and L-CDR3, wherein L-CDR1 is selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 21, and a sequence that differs from anyone of SEQ ID NOs: 15, 18, or 21 by one or two substitutions, deletions, or additions, the amino acid sequence of L-CDR2 is selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 22, and a sequence that differs from anyone of SEQ ID NOs: 16, 19, or 22 by one or two substitutions, deletions, or additions, and the amino acid sequence of L-CDR3 is selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 23, and a sequence that differs from anyone of SEQ ID NOs: 17, 20, or 23 by one or two substitutions, deletions, or additions.
A device for determining a cellular-bound analyte in a liquid sample includes a separation matrix with at least one indicator zone. The indicator zone includes a first antibody directed against the cellular-bound analyte or a fragment thereof and a binding element directed against the first antibody. The first antibody is an incomplete antibody. The separation matrix can be designed in the form of the membrane of a lateral flow assay device or as a gel matrix. For example, the device can include a membrane with a charging zone for applying the liquid sample, at least one indicator zone which can interact with the cellular-bound analyte, and at least one absorption region, which absorbs the liquid after passing the indicator zone. The indicator zone lies between the charging zone and the absorption region. The indicator zone can include an antibody directed against the cellular-bound analyte or a fragment thereof and a binding element directed against the first antibody.
G01N 33/80 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir les groupes ou les types sanguins
G01N 33/558 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant la diffusion ou la migration de l'anticorps ou de l'antigène
G01N 33/559 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant la diffusion ou la migration de l'anticorps ou de l'antigène dans un gel, p. ex. technique d'Ouchterlony
23.
SYSTEMS AND METHODS FOR BIOLOGICAL SAMPLE LABORATORY SCREENING
Systems and methods for guiding the management of blood/plasma screening laboratory workflow are disclosed. A system for analyzing biological samples can include centrifuges, pooling devices, biological sample analyzing devices, and a processor to monitor operation of the centrifuges, the pooling devices, and the biological sample analyzing devices. The processor can track the progress of the biological samples and generate progress indications In response to determining that an external control is present, the system can prevent release of the biological component to the biological sample analyzing device until the external control is also loaded into the analyzer. In response to a component of a biological sample being grouped into more than one pool or not intended to be pooled, the system can generate a warning. The system can provide a chronology of states, display the status of instruments/biological samples, indicate what components need operator attention, and search the status of samples/tests.
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
G01N 35/02 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse
24.
METHODS AND COMPOSITIONS FOR DETECTING SARS-COV-2 NUCLEIC ACID
This application relates to the medical field of COVID-19 diagnosis, and in particular, it relates to methods for detecting SARS-CoV-2 nucleic acids in a sample. This application also relates to combinations of oligomers for determining the presence or absence of SARS-CoV-2 in a Sample.
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
25.
ANTI D-DIMER RECOMBINANT ANTIBODIES, METHODS AND USES THEREOF
This application relates to anti-D-Dimer recombinant antibodies that specifically bind to fibrin and fibrinogen degradation products (FDP) such as D-Dimer, fragment DD and fragment D with high binding affinity and do not bind to fragment E and fibrinogen. The present invention also refers to methods and assays for detection of D-Dimer and FDP fragments in samples using said recombinant antibodies.
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C07K 16/36 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de coagulation sanguine
G01N 33/86 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir le temps de coagulation du sang
26.
Compositions, methods and/or kits comprising a recombinant human CD38- extracellular domain
A composition that binds to an anti-CD38 antibody includes a specific sequence of a recombinant soluble form of an extracellular domain of CD38 and/or a fragment thereof that interferes with binding activity of the anti-CD38 antibody. The composition can be included in a kit for bio-monitoring research and diagnostic assays. The composition can be used to neutralize an anti-CD38 antibody in a sample and/or to select a suitable red blood cell unit for a patient treated with anti-CD38 antibodies.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/80 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir les groupes ou les types sanguins
27.
DUAL QUENCHING ASSAY FOR MULTIPLEX DETECTION OF TARGET NUCLEIC ACIDS
The present invention relates to a method for detecting at least one target nucleic acid sequence from a nucleic acid mixture by a double quenched assay. The double quenched assay of the method exploits a novel approach for melting temperature mediated identification of multiple target nucleic acid sequences. The invention further relates to a kit of parts.
C12Q 1/6818 - Tests d’hybridation caractérisés par les moyens de détection impliquant l’interaction de plusieurs marqueurs, p. ex. transfert d’énergie de résonance
28.
NOVEL MAMMALIAN EXPRESSED HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE PROTEIN ANTIGENS
Novel mammalian expressed human immunodeficiency virus envelope Protein antigens Various embodiments of the invention relate to polypeptides comprising 1-10 or more epitopes of the HIV envelope protein and a fusion protein, wherein the polypeptide lacks the transmembrane domain of the HIV gp41 protein. Such polypeptides may be expressed in mammalian cells, such as human cells, to produce, for example, polypeptides that are useful in developing novel anti-HIV antibodies. Polypeptides described herein and novel antibodies developed therefrom are generally useful for medical diagnostics, and they may also be useful in the prophylactic and therapeutic treatment of HIV.
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
29.
Method to homogenize parvovirus B19 in clinical samples
Various aspects of the invention relate to compositions and methods of analyzing blood plasma, blood serum, and manufacturing pools of plasma-derived products wherein an anionic surfactant is added to an aliquot of the blood plasma, blood serum, or manufacturing pool prior to analysis, and the counterion of the anionic surfactant is not sodium ion. The anionic surfactant may be, for example, lauryl sulfate. The counterion of the anionic surfactant may be, for example, lithium ion.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Custom manufacture of pharmaceutical, veterinary and diagnostic preparations and substances; custom manufacture of biopharmaceuticals; biomanufacturing for others, namely, processing of biopharmaceutical materials for others; consultancy services relating to manufacturing processes for pharmaceutical, veterinary and diagnostic substances; custom manufacture of recombinant proteins Chemical preparations for use in industry; chemicals used in science; reagents for scientific purposes; diagnostic preparations, namely, antigens and antibodies for scientific purposes; testing kits for scientific purposes predominantly consisting of reagents; proteins for industrial use, namely, antigens and antibodies; nucleic acids for laboratory use, namely, nucleic acid for the production of proteins produced by biochemical and/or genetic engineering methods Antibacterial pharmaceuticals; diagnostic veterinary preparations; diagnostic preparations for medical purposes; diagnostic preparations, namely, antigens and antibodies for medical purposes for use in disease testing; pharmaceutical, veterinary and/or diagnostic preparations and substances produced by biochemical and/or genetic engineering methods, namely, antivirals and diagnostic preparations for veterinary and medical use; reagents for medical purposes; tests and test kits for medical and pharmaceutical purposes, namely, drug testing kits comprised of medical diagnostic reagents and assays that testing bodily fluids Scientific and technological services, namely, pharmaceutical and new product research and design; scientific research and development services; research in the chemical, medical, and/or biochemical field; development of pharmaceutical, veterinary medicine and medical diagnostic substances and products and pharmaceutical research regarding methods for the manufacture thereof, namely, using biotechnological and genetically-engineered means; process development services in relation to pharmaceutical, veterinary and diagnostic substances, namely, consulting regarding the development of pharmaceutical preparations and medicines; technical consultancy in the pharmaceutical, veterinary and diagnostic sector, namely, technical consulting in the field of pharmaceutical studies; new product development services in relation to recombinant protein technology and development
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Custom manufacture of pharmaceutical, veterinary and diagnostic preparations and substances; custom manufacture of biopharmaceuticals; biomanufacturing for others, namely, processing of biopharmaceutical materials for others; consultancy services relating to manufacturing processes for pharmaceutical, veterinary and diagnostic substances; custom manufacture of recombinant proteins Chemical preparations for use in industry; chemicals used in science; reagents for scientific purposes; diagnostic preparations, namely, antigens and antibodies for scientific purposes; testing kits for scientific purposes predominantly consisting of reagents; proteins for industrial use, namely, antigens and antibodies; nucleic acids for laboratory use, namely, nucleic acid for the production of proteins produced by biochemical and/or genetic engineering methods Antibacterial pharmaceuticals; diagnostic veterinary preparations; diagnostic preparations for medical purposes; diagnostic preparations, namely, antigens and antibodies for medical purposes for use in disease testing; pharmaceutical, veterinary and/or diagnostic preparations and substances produced by biochemical and/or genetic engineering methods, namely, antivirals and diagnostic preparations for veterinary and medical use; reagents for medical purposes; tests and test kits for medical and pharmaceutical purposes, namely, drug testing kits comprised of medical diagnostic reagents and assays that testing bodily fluids Scientific and technological services, namely, pharmaceutical and new product research and design; scientific research and development services; research in the chemical, medical, and/or biochemical field; development of pharmaceutical, veterinary medicine and medical diagnostic substances and products and pharmaceutical research regarding methods for the manufacture thereof, namely, using biotechnological and genetically-engineered means; process development services in relation to pharmaceutical, veterinary and diagnostic substances, namely, consulting regarding the development of pharmaceutical preparations and medicines; technical consultancy in the pharmaceutical, veterinary and diagnostic sector, namely, technical consulting in the field of pharmaceutical studies; new product development services in relation to recombinant protein technology and development
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical preparations for use in industry; chemicals used in science; reagents for scientific purposes; diagnostics, in particular antigens and antibodies, for scientific purposes; testing kits for scientific purposes, predominantly consisting of reagents; proteins, in particular antigens and antibodies; nucleic acids, in particular for the production of proteins produced by biochemical and/or genetic engineering methods. Pharmaceuticals; veterinary preparations; preparations for medical purposes; diagnostics, in particular antigens and antibodies, for medical purposes; pharmaceutical, veterinary and/or diagnostic preparations and substances produced by biochemical and/or genetic engineering methods; reagents for medical purposes; tests and test kits for medical and pharmaceutical purposes. Custom manufacture of pharmaceutical, veterinary and diagnostic preparations and substances; custom manufacture of biopharmaceuticals; processing of biopharmaceutical materials for others; consultancy services relating to manufacturing processes for pharmaceutical, veterinary and diagnostic substances; custom manufacture of recombinant proteins. Scientific and technological services and research and design relating thereto; scientific research and development services; research in the chemical, medical, and/or biochemical field; development of pharmaceutical, veterinary and diagnostic substances and products, and methods for the manufacture thereof, in particular using biotechnological and genetically-engineered means; process development services in relation to pharmaceutical, veterinary and diagnostic substances; technical consultancy in the pharmaceutical, veterinary and diagnostic sector; services in relation to recombinant protein technology and development.
33.
Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors PD1 and PD-L1
Fusion proteins comprising an extracellular domain of PD1 (programmed cell death protein-1) protein and/or an extracellular domain of PD-L1 (programmed cell death-ligand 1 protein (CD274 or B7-H1)) protein. Portions of the extracellular domains are expressed in specific configurations and purified as protein and used in immunoassays to monitor the circulating levels of biotherapeutic antibodies to these proteins. Also described is a method of determining the amount of circulating levels of a biotherapeutic antibody in a biological sample obtained from a patient, wherein a patient has undergone at least one dose of immunotherapy.
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A device for breaking cells that has a reactor with a reaction chamber, an agitator, a cooling jacket, a cooling jacket inlet, a cooling jacket outlet, a sampling port, and a temperature probe insertion fitting, and a motor suitable for mounting the reactor on its top and which is operably connected with the agitator. A system for breaking cells comprising at least one device, at least one temperature probe inserted in the temperature probe insertion fitting of the device, a cooling system operably connected to the temperature probe, and an electronic control panel. The cooling system has at least one solenoid valve, each device of the system having one corresponding solenoid valve.
C12M 1/02 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens d'agitationAppareillage pour l'enzymologie ou la microbiologie avec des moyens d'échange de chaleur
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
Disclosed are nucleic acid oligomers, including amplification oligomers, detection probes, and capture probes, for detection of Plasmodium species nucleic acid in a sample. Also disclosed are methods of specific nucleic acid amplification and detection, including amplification and detection of target nucleic acid in real time, using the disclosed oligomers, as well as corresponding reaction mixtures and kits.
C12Q 1/6893 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les protozoaires
Plasmodium Plasmodium species nucleic acid in a sample. Also disclosed are methods of specific nucleic acid amplification and detection, including amplification and detection of target nucleic acid in real time, using the disclosed oligomers, as well as corresponding reaction mixtures and kits.
C12Q 1/6893 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les protozoaires
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
Produits et services
Mixing weighing scales to monitor the collection of blood samples. Medical apparatus and instruments, namely blood sample mixers; fixed and portable tube sealing devices for filling blood bags for medical use; devices for the compression of tubes for filling blood bags for medical use.
38.
COMPOSITION COMPRISING RECOMBINANT GpIba RECEPTOR PROTEIN
Various aspects of the invention relate to recombinant polypeptides that specifically bind human von Willebrand Factor. Such recombinant polypeptides typically include a modified extracellular domain of platelet glycoprotein Ibα that typically comprises at least one mutation selected from G233T, D235V, and K237V, and such recombinant polypeptides optionally include an oligomerization domain.
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 14/745 - Facteurs de coagulation sanguine ou de fibrinolyse
C12Q 1/56 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des facteurs de coagulation du sang, p. ex. faisant intervenir la thrombine, la thromboplastine, le fibrinogène
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
39.
A METHOD TO DETERMINE PARVOVIRUS B19 IN CLINICAL SAMPLES
Various aspects of the invention relate to compositions and methods of analyzing blood plasma, blood serum, and manufacturing pools of plasma-derived products wherein an anionic surfactant is added to an aliquot of the blood plasma, blood serum, or manufacturing pool prior to analysis, and the counterion of the anionic surfactant is not sodium ion. The anionic surfactant may be, for example, lauryl sulfate. The counterion of the anionic surfactant may be, for example, lithium ion.
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
40.
IMMUNOASSAYS AND ENGINEERED PROTEINS FOR MONITORING ANTIBODY TREATMENTS TO THE IMMUNE CHECKPOINT INHIBITORS PD1 AND PD-L1
Fusion proteins comprising an extracellular domain of PD1 (programmed cell death protein-1) protein and/or an extracellular domain of PD-L1 (programmed cell death-ligand 1 protein (CD274 or B7-H1)) protein. Portions of the extracellular domains are expressed in specific configurations and purified as protein and used in immunoassays to monitor the circulating levels of biotherapeutic antibodies to these proteins. Also described is a method of determining the amount of circulating levels of a biotherapeutic antibody in a biological sample obtained from a patient, wherein a patient has undergone at least one dose of immunotherapy.
Systems and methods for guiding the management of blood and/or plasma screening laboratory workflow are disclosed. In some embodiments, a system for analyzing biological samples includes centrifuges, pooling devices, biological sample analyzing devices, and a processor to monitor operation of the centrifuges, the pooling devices, and the biological sample analyzing devices. The processor can track the progress of analysis of the biological samples and generate progress indications via the graphical user interface. In response to determining that an external control is present, the system can prevent release of the biological component to the biological sample analyzing device to perform analysis until the external control is also loaded into the analyzer. In response to a determination that a component of a biological sample is grouped into more than one pool or not intended to be pooled, the system can generate a warning via the graphical user interface. The system can provide a chronology of states, display the status of instruments and biological samples, indicate what components need operator attention, and search and display the status of samples and tests. The system can prevent unintended use, including duplicate testing.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 1/38 - Dilution, dispersion ou mélange des échantillons
G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
G01N 35/02 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse
42.
SYSTEMS AND METHODS FOR BIOLOGICAL SAMPLE LABORATORY SCREENING
Systems and methods for guiding the management of blood and/or plasma screening laboratory workflow are disclosed. In some embodiments, a system for analyzing biological samples includes centrifuges, pooling devices, biological sample analyzing devices, and a processor to monitor operation of the centrifuges, the pooling devices, and the biological sample analyzing devices. The processor can track the progress of analysis of the biological samples and generate progress indications via the graphical user interface. In response to determining that an external control is present, the system can prevent release of the biological component to the biological sample analyzing device to perform analysis until the external control is also loaded into the analyzer. In response to a determination that a component of a biological sample is grouped into more than one pool or not intended to be pooled, the system can generate a warning via the graphical user interface. The system can provide a chronology of states, display the status of instruments and biological samples, indicate what components need operator attention, and search and display the status of samples and tests. The system can prevent unintended use, including duplicate testing.
G01N 1/38 - Dilution, dispersion ou mélange des échantillons
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
G01N 35/02 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse
G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
43.
NOVEL MAMMALIAN EXPRESSED HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE PROTEIN ANTIGENS
Various embodiments of the invention relate to polypeptides comprising 1-10 or more epitopes of the HIV envelope protein and a fusion protein, wherein the polypeptide lacks the transmembrane domain of the HIV gp41 protein. Such polypeptides may be expressed in mammalian cells, such as human cells, to produce, for example, polypeptides that are useful in developing novel anti-HIV antibodies. Polypeptides described herein and novel antibodies developed therefrom are generally useful for medical diagnostics, and they may also be useful in the prophylactic and therapeutic treatment of HIV.
A61K 39/21 - Retroviridae, p. ex. virus de l'anémie infectieuse équine
C07K 14/155 - Lentiviridae, p. ex. virus du déficit immunitaire humain [HIV], virus visna-maedi ou virus de l'anémie infectieuse équine
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
C12N 15/49 - Lentiviridae, virus de l'immunodéficience comme le VIH, virus visna-maedi, virus de l'anémie infectieuse équine
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
44.
NOVEL MAMMALIAN EXPRESSED HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE PROTEIN ANTIGENS
Various embodiments of the invention relate to polypeptides comprising 1-10 or more epitopes of the HIV envelope protein and a fusion protein, wherein the polypeptide lacks the transmembrane domain of the HIV gp41 protein. Such polypeptides may be expressed in mammalian cells, such as human cells, to produce, for example, polypeptides that are useful in developing novel anti-HIV antibodies. Polypeptides described herein and novel antibodies developed therefrom are generally useful for medical diagnostics, and they may also be useful in the prophylactic and therapeutic treatment of HIV.
C07K 14/155 - Lentiviridae, p. ex. virus du déficit immunitaire humain [HIV], virus visna-maedi ou virus de l'anémie infectieuse équine
A61K 39/21 - Retroviridae, p. ex. virus de l'anémie infectieuse équine
C12N 15/49 - Lentiviridae, virus de l'immunodéficience comme le VIH, virus visna-maedi, virus de l'anémie infectieuse équine
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
45.
COMPOSITIONS, METHODS AND/OR KITS COMPRISING A RECOMBINANT HUMAN CD38-EXTRACELLULAR DOMAIN
A composition that binds to an anti-CD38 antibody includes a specific sequence of a recombinant soluble form of an extracellular domain of CD38 and/or a fragment thereof that interferes with binding activity of the anti-CD38 antibody. The composition can be included in a kit for bio-monitoring research and diagnostic assays. The composition can be used to neutralize an anti-CD38 antibody in a sample and/or to select a suitable red blood cell unit for a patient treated with anti-CD38 antibodies
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
46.
Device and method for detecting blood group antigens by means of an incomplete antibody
The invention relates to a device for determining a cellular-bound analyte in a liquid sample, comprising a separation matrix with at least one indicator zone. The invention is characterized in that the indicator zone comprises a first antibody directed against the cellular-bound analyte or a fragment thereof and a binding element directed against the first antibody, the first antibody being an incomplete antibody. The separation matrix is preferably designed in the form of the membrane of a lateral flow assay device or as a gel matrix. In a particularly preferable manner, the device comprises a membrane (2) with a charging zone (5) for applying the liquid sample, at least one indicator zone which can interact with the cellular-bound analyte, and at least one absorption region (3) which absorbs the liquid after passing the indicator zone. The indicator zone lies between the charging zone (5) and the absorption region (3). The invention is characterized in that the indicator zone comprises an antibody directed against the cellular-bound analyte or a fragment thereof and a binding element directed against the first antibody, the first antibody being an incomplete antibody.
G01N 33/558 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant la diffusion ou la migration de l'anticorps ou de l'antigène
G01N 33/80 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir les groupes ou les types sanguins
G01N 33/559 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant la diffusion ou la migration de l'anticorps ou de l'antigène dans un gel, p. ex. technique d'Ouchterlony
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Chemicals used in diagnostics, industry and science; DNA and
RNA preparations for scientific and industrial purposes;
proteins for use within science; chemical reagents for
scientific purposes; diagnostic reagents for scientific
purposes; diagnostic test materials for scientific purposes;
diagnostic agents, preparations and substances for
scientific purposes; assays for research purposes;
biochemical reagents for analyses of nucleic acids,
nucleotides, oligonucleotides, DNA and RNA; chemical
reagents for other than medicinal and veterinary purposes;
biochemical reagents commonly known as probes, for analyses
of genes, nucleotides, oligonucleotides, nucleic acids and
for detecting DNA, RNA and microRNA; biochemical kits
comprising reagents, not for medicinal and veterinary
purposes, for analyses of genes, nucleic acids, nucleotides,
oligonucleotides, DNA, RNA and microRNA. Pharmaceutical, medical and veterinary preparations;
chemico-pharmaceutical preparations; DNA and RNA
preparations for medical and veterinary purposes; biological
preparations for medical and veterinary purposes; chemical
preparations for therapeutic use; reagents for medical
diagnosis and/or analysis; clinical medical reagents;
diagnostic preparations for medical and veterinary purposes;
diagnostic test materials for medical use; diagnostic
agents, preparations and substances for medical use.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Chemicals used in industry and science; chemicals used in diagnostics, namely, chemical substances for analyses in laboratories other than for medical or veterinary purposes; DNA and RNA diagnostic preparations for scientific and industrial purposes; proteins in raw material form for use within science; chemical reagents for scientific purposes; diagnostic reagents for scientific purposes; diagnostic test materials in the nature of chemical test kits for non-medical DNA testing and PCR based assays for scientific purposes; diagnostic agents, preparations and substances for scientific purposes; assays for research purposes; biochemical reagents for non-medical analyses of nucleic acids, nucleotides, oligonucleotides, DNA and RNA; chemical reagents for other than medicinal and veterinary purposes; biochemical reagents commonly known as probes, for analyses of genes, nucleotides, oligonucleotides, nucleic acids and for detecting DNA, RNA and microRNA for laboratory and research use; biochemical kits comprising reagents, not for medicinal and veterinary purposes, for analyses of genes, nucleic acids, nucleotides, oligonucleotides, DNA, RNA and microRNA Pharmaceutical, medical and veterinary preparations, namely, for treatment, prevention or alleviation of infectious diseases; chemico-pharmaceutical preparations, namely, for treatment, prevention or alleviation of infectious diseases; DNA and RNA diagnostic preparations for medical and veterinary purposes; biological preparations for medical and veterinary purposes, namely, for treatment, prevention or alleviation of infectious diseases; chemical preparations for therapeutic use, namely, for treatment, prevention or alleviation of infectious diseases; reagents for medical diagnosis and/or therapeutic analysis; clinical medical reagents; diagnostic preparations for medical and veterinary purposes; diagnostic test materials, namely, identity tests comprised of reagents, for medical use; diagnostic agents, preparations and substances for medical use
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemicals used in diagnostics, industry and science; DNA and RNA preparations for scientific and industrial purposes; proteins for use within science; chemical reagents for scientific purposes; diagnostic reagents for scientific purposes; diagnostic test materials for scientific purposes; diagnostic kits for scientific purposes; assays for research purposes; biochemical reagents for analyses of nucleic acids, nucleotides, oligonucleotides, DNA and RNA; chemical reagents for other than medicinal and veterinary purposes; biochemical reagents commonly known as probes, for analyses of genes, nucleotides, oligonucleotides, nucleic acids and for detecting DNA, RNA and microRNA; biochemical kits comprising reagents, not for medicinal and veterinary purposes, for analyses of genes, nucleic acids, nucleotides, oligonucleotides, DNA, RNA and microRNA. Pharmaceutical, medical and veterinary preparations; chemico-pharmaceutical preparations; DNA and RNA preparations for medical and veterinary purposes; biological preparations for medical and veterinary purposes; chemical preparations for therapeutic use; reagents for medical diagnosis and/or analysis; clinical medical reagents; diagnostic preparations for medical and veterinary purposes; diagnostic test materials for medical use; diagnostic kits for medical use. Scientific and technological services and research and design relating thereto; industrial analysis and research services; gene research; research and development related to medical and veterinary drugs and preparations, research and development related to biotechnology; research and development related to healthcare; molecular research; development of processes and methods for medical and veterinary purposes; development of preparations for medical and veterinary purposes.
50.
DEVICE AND METHOD FOR DETECTING BLOOD GROUP ANTIGENS BY MEANS OF AN INCOMPLETE ANTIBODY
The invention relates to a device for determining a cellular-bound analyte in a liquid sample, comprising a separation matrix with at least one indicator zone. The invention is characterized in that the indicator zone comprises a first antibody directed against the cellular-bound analyte or a fragment thereof and a binding element directed against the first antibody, the first antibody being an incomplete antibody. The separation matrix is preferably designed in the form of the membrane of a lateral flow assay device or as a gel matrix. In a particularly preferable manner, the device comprises a membrane (2) with a charging zone (5) for applying the liquid sample, at least one indicator zone which can interact with the cellular-bound analyte, and at least one absorption region (3) which absorbs the liquid after passing the indicator zone. The indicator zone lies between the charging zone (5) and the absorption region (3). The invention is characterized in that the indicator zone comprises an antibody directed against the cellular-bound analyte or a fragment thereof and a binding element directed against the first antibody, the first antibody being an incomplete antibody.
G01N 33/558 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet utilisant la diffusion ou la migration de l'anticorps ou de l'antigène
G01N 33/80 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir les groupes ou les types sanguins
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
[ anti-viral, anti-infective, anti-cancer, anti-psoriatic, and immunoregulatory preparations for human and animal use; storage media for corneas; ] kits comprising chemical reagents for diagnosing medical conditions all for in vitro use [ ; hormones; and peptides ]
